These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24605971)

  • 1. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
    Asakawa T; Hirakawa A; Hamada C
    J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pragmatic dose-finding approach using short-term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials.
    Asakawa T; Hamada C
    Pharm Stat; 2013; 12(5):315-27. PubMed ID: 24019203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.
    Zhong W; Koopmeiners JS; Carlin BP
    Stat Med; 2012 Dec; 31(29):3885-95. PubMed ID: 22807126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-stage algorithm for designing phase I cancer clinical trials for two new molecular entities.
    Su Z
    Contemp Clin Trials; 2010 Jan; 31(1):105-7. PubMed ID: 19879974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
    Liu S; Pan H; Xia J; Huang Q; Yuan Y
    Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.